# MDRTB in India

Anthropological perspectives

Jens Seeberg

iDRESS-meeting 9 January 2015

## Background for current work on MDRTB

- Work as Health Systems Research Advisor in Danida-supported TB control project in Odisha in India 2003-5
- Director of project on utilization of (primary and secondary) private healthcare among people living in poor urban neighbourhoods in four cities in India, Indonesia and Thailand 2004-8



#### Connecting Pills and People:

An Ethnography of the Pharmaceutical Nexus in Odisha, India

#### Jens Seeberg

Article first published online: 11 JUN 2012 DOI: 10.1111/j.1548-1387.2012.01200.x

© 2012 by the American Anthropological Association



Medical Anthropology Quarterly

Volume 26, Issue 2, pages 182–200, June 2012



### Social Science & Medicine

Issue


Volume 102, February 2014, Pages 49-57



Treatment seeking and health financing in selected poor urban neighbourhoods in India, Indonesia and Thailand

Jens Seeberg<sup>a,</sup> ♣ · ▶ A, Supasit Pannarunothai<sup>b</sup>, Retna Siwi Padmawati<sup>c</sup>, Laksono Trisnantoro<sup>c</sup>, Nupur Barua<sup>d</sup>, Chandrakant S. Pandav<sup>e</sup>

# MDR-TB cases estimated to occur among notified pulmonary TB cases, 2013



The boundaries and names shown and the designations used on this map do not imply the expression of any opinion whatsoever on the part of the World Health Organization concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted lines on maps represent approximate border lines for which there may not yet be full agreement. © WHO 2014. All rights reserved



cases of MDR-TB estimated among TB patients reported by national TB programmes in 2013



patients eligible for MDR-TB treatment

(136 000 out of 300 000) were detected and reported in 2013

97 000

people with TB were started on second-line treatment for MDR-TB in 2013, leaving many patients on waiting lists for treatment


...meaning that 16% of the estimated MDRTB patients could be treated in 2013

48% 🍙

of MDR-TB patients globally had a successful treatment outcome

Five out of the 27 high MDR-TB countries achieved a treatment success rate of ≥70%

## Trends for notified TB and MDR-TB cases in India



BUT: For 2013, WHO estimates that there are 61,000 new MDRTB cases in India among notified pulmonary TB cases alone

https://extranet.who.int/sree/Reports?op=vs&path=/WHO\_HQ\_Reports/G2/PROD/EXT/MDRTB\_Indicators\_charts

## Research orientations: 1 – private sector

Analysis of Private healthcare sector in 00s, using Odisha as a case.

### **Conclusions:**

- Unregulated and highly competitive private sector market driven by pharma industry undermines medical rationale for drug use.
- Primary motive for treatment is profit, not health.

2.6% (37 166/1 410 880).<sup>3</sup> This figure also highlights the private sector's dismal record of involvement in TB control program activities. Given the current heavy burden of multidrug-resistant tuberculosis (MDR-TB) in India, it is important to understand where and how anti-tuberculosis medicines are being used in the private sector, outside the RNTCP.

A case study of Lupin Pharmaceuticals, a major supplier of anti-tuberculosis medicines in India, has indicated that pharmaceutical companies and their representatives play a strong role in the marketing and promotion of anti-tuberculosis drugs in the private sector.<sup>2</sup> An ethnographic study in India's Orissa State based on 'actor-network' theory describes a network of pharmaceutical sector, private practitioners and chemists and how the pharmaceutical industry exploited weak links in the health system to push drugs aggressively through pharmacists or chemists and sometimes even through illegal channels.4 These studies highlight that a symbiotic relationship exists among the different actors in the

network, as stated above. However, there may at

## Research orientations: 2 – DOTS from patient perspective

- Analysing case of TB patient who died (Shankar Pradhan). NB: resistance status unknown!
- His trajectory exposes a long series of weak links in RNTCP and in DOTS in general
- Currently working on a detailed mapping of the micro-level elements of programme failure reflected in Shankar's case
- Intention to discuss these in relation to the latest 'End TB' strategy, recently launched by WHO: What lessons have been included in this new startegy, and what lessons have been ignored?



# Research orientations: 3 – MDRTB from the perspective of bacteria

- What do we learn if we turn things around and consider the world from the perspective of Mycobacteria tuberculosis?
  - Treatment may be considered the epidemic, and concepts such as exposure and immunity are foregrounded
  - Understanding the role of phages and interbacteria communication
  - Working around the imperative of increased access in spite of insufficient health systems
  - The political economy of Mycobacteria tuberculosis



# Collaborative perspectives

• Linking anthropological exploration of treatment trajectories of TB cases with microbiology, incl. MDRTB testing (e.g. India, Nepal); + epidemiological component (main hurdle may not be funding but research permit, we'd need strong Indian partners)

• Linking, in similar ways, studies of e.g. MRSA in Denmark/Europe...